135 related articles for article (PubMed ID: 37114884)
1. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
Lee YH; Song GG
Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
[TBL] [Abstract][Full Text] [Related]
2. Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis.
Lee YH; Song GG
Pharmacogenomics J; 2023 Nov; 23(6):210-216. PubMed ID: 37149714
[TBL] [Abstract][Full Text] [Related]
3. Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.
Mahmoud I; Moalla M; Ben Tekaya A; Bouden S; Rouached L; Tekaya R; Saidane O; Gorji Y; Elleuch M; Laatar A; Hamdi W; Abdelmoula L; Sfar I
Drug Metab Pers Ther; 2023 Jun; 38(2):155-162. PubMed ID: 36919284
[TBL] [Abstract][Full Text] [Related]
4. Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.
Lee YH; Bae SC; Song GG
Rheumatol Int; 2014 Oct; 34(10):1409-15. PubMed ID: 24728031
[TBL] [Abstract][Full Text] [Related]
5. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
Lee YH; Bae SC
Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
[TBL] [Abstract][Full Text] [Related]
6. Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.
Lee YH; Choi SJ; Ji JD; Song GG
Pharmacogenomics; 2016 Aug; 17(13):1465-77. PubMed ID: 27490376
[TBL] [Abstract][Full Text] [Related]
7. FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2015; 33(5):647-54. PubMed ID: 26314337
[TBL] [Abstract][Full Text] [Related]
8. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
[TBL] [Abstract][Full Text] [Related]
9. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
10. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
[TBL] [Abstract][Full Text] [Related]
11. Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis.
Song GG; Lee YH
Mol Biol Rep; 2013 Aug; 40(8):4985-93. PubMed ID: 23649770
[TBL] [Abstract][Full Text] [Related]
12. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.
Montes A; Perez-Pampin E; Joven B; Carreira P; Fernández-Nebro A; Del Carmen Ordóñez M; Navarro-Sarabia F; Moreira V; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Cañete JD; de la Serna AR; Magallares B; Narváez J; Gómez-Reino JJ; Gonzalez A
Pharmacogenomics; 2015; 16(4):333-45. PubMed ID: 25823782
[TBL] [Abstract][Full Text] [Related]
13. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
14. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
Ying HQ; Wang F; Chen XL; He BS; Pan YQ; Jie C; Liu X; Cao WJ; Peng HX; Lin K; Wang SK
Oncotarget; 2015 Sep; 6(29):28071-83. PubMed ID: 26363448
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B.
Morgan AW; Barrett JH; Griffiths B; Subramanian D; Robinson JI; Keyte VH; Ali M; Jones EA; Old RW; Ponchel F; Boylston AW; Situnayake RD; Markham AF; Emery P; Isaacs JD
Arthritis Res Ther; 2006; 8(1):R5. PubMed ID: 16356189
[TBL] [Abstract][Full Text] [Related]
16. Influence of the
Márquez Pete N; Maldonado Montoro MDM; Pérez Ramírez C; Martínez Martínez F; Martínez de la Plata JE; Daddaoua A; Jiménez Morales A
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34207385
[TBL] [Abstract][Full Text] [Related]
17. Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis.
Lee YH; Ji JD; Song GG
J Rheumatol; 2008 Nov; 35(11):2129-35. PubMed ID: 18843786
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
Ghesquières H; Cartron G; Seymour JF; Delfau-Larue MH; Offner F; Soubeyran P; Perrot A; Brice P; Bouabdallah R; Sonet A; Dupuis J; Casasnovas O; Catalano JV; Delmer A; Jardin F; Verney A; Dartigues P; Salles G
Blood; 2012 Sep; 120(13):2650-7. PubMed ID: 22885164
[TBL] [Abstract][Full Text] [Related]
19. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Kjersem JB; Skovlund E; Ikdahl T; Guren T; Kersten C; Dalsgaard AM; Yilmaz MK; Fokstuen T; Tveit KM; Kure EH
BMC Cancer; 2014 May; 14():340. PubMed ID: 24884501
[TBL] [Abstract][Full Text] [Related]
20. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.
Ghesquières H; Larrabee BR; Haioun C; Link BK; Verney A; Slager SL; Ketterer N; Ansell SM; Delarue R; Maurer MJ; Fitoussi O; Habermann TM; Peyrade F; Dogan A; Molina TJ; Novak AJ; Tilly H; Cerhan JR; Salles G
Hematol Oncol; 2017 Dec; 35(4):447-455. PubMed ID: 27282998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
